BofA analyst Tazeen Ahmad initiated coverage of Belite Bio (BLTE) with a Buy rating and $195 price target Tinlarebant is an oral, once-daily RPB4 antagonist that has produced positive Phase 3 results with the potential to be the first-approved therapy for Stargardt disease type 1, the analyst tells investors. The firm thinks tinlarebant for STGD1 represents “a significant commercial opportunity given the high unmet need,” the analyst tells investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLTE:
- Belite Bio initiated with an Overweight at Morgan Stanley
- Belite Bio: Tinlarebant’s First-Mover Advantage in STGD1 Supports Multi‑Billion Revenue Outlook and Further Upside Potential
- Belite Bio participates in a conference call with H.C. Wainwright
- Belite Bio Prices $350 Million ADS Offering to Boost Drug Development
- Belite Bio price target raised to $200 from $140 at Maxim